Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Basal Cell Carcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Skin Cancer (1090)

Merkel Cell Carcinoma (28)

Squamous Cell Skin Cancer (22)

Skin Cancer (1090)

Merkel Cell Carcinoma (28)

Squamous Cell Skin Cancer (22)

›

No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	imiquimod Sensitive: A1 - Approval imiquimod Sensitive : A1	imiquimod Sensitive: A1 - Approval imiquimod Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	celecoxib Resistant: A2 - Guideline celecoxib Resistant : A2	celecoxib Resistant: A2 - Guideline celecoxib Resistant : A2
SMO mutation	Basal Cell Carcinoma	SMO mutation	Basal Cell Carcinoma	vismodegib Resistant: B - Late Trials vismodegib Resistant : B	vismodegib Resistant: B - Late Trials vismodegib Resistant : B
PD-L1 expression	Basal Cell Carcinoma	PD-L1 expression	Basal Cell Carcinoma	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
TMB-H	Basal Cell Carcinoma	TMB-H	Basal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
GLI1 overexpression	Basal Cell Carcinoma	GLI1 overexpression	Basal Cell Carcinoma	vismodegib Resistant: C3 – Early Trials vismodegib Resistant : C3	vismodegib Resistant: C3 – Early Trials vismodegib Resistant : C3
GAS1 underexpression	Basal Cell Carcinoma	GAS1 underexpression	Basal Cell Carcinoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
SMO W535L	Basal Cell Carcinoma	SMO W535L	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
SMO Q477E	Basal Cell Carcinoma	SMO Q477E	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
SMO D473H	Basal Cell Carcinoma	SMO D473H	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
SMO S533N	Basal Cell Carcinoma	SMO S533N	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
SMO D473G	Basal Cell Carcinoma	SMO D473G	Basal Cell Carcinoma	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4	sonidegib Resistant: C4 – Case Studies sonidegib Resistant : C4
PTCH1 1504-1G>T + TMB-H	Basal Cell Carcinoma	PTCH1 1504-1G>T + TMB-H	Basal Cell Carcinoma	nivolumab + vismodegib Sensitive: C4 – Case Studies nivolumab + vismodegib Sensitive : C4	nivolumab + vismodegib Sensitive: C4 – Case Studies nivolumab + vismodegib Sensitive : C4
PTCH1 S616G	Basal Cell Carcinoma	PTCH1 S616G	Basal Cell Carcinoma	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4